{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:46:31Z","timestamp":1761961591396,"version":"build-2065373602"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,7,28]],"date-time":"2010-07-28T00:00:00Z","timestamp":1280275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s11926-010-0125-y","type":"journal-article","created":{"date-parts":[[2010,7,27]],"date-time":"2010-07-27T06:06:05Z","timestamp":1280210765000},"page":"325-331","source":"Crossref","is-referenced-by-count":20,"title":["Update on Biologic Therapy in the Management of Axial Spondyloarthritis"],"prefix":"10.1007","volume":"12","author":[{"given":"Frank","family":"Heldmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Dybowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ertan","family":"Saracbasi-Zender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claas","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,28]]},"reference":[{"key":"125_CR1","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/rheumatology\/keh205","volume":"43","author":"J Braun","year":"2004","unstructured":"Braun J, Sieper J: Biological therapies in the spondyloarthritides\u2014the current state. Rheumatology 2004, 43:1072\u20131084.","journal-title":"Rheumatology"},{"key":"125_CR2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J: Ankylosing spondylitis. Lancet 2007, 369:1379\u20131390.","journal-title":"Lancet"},{"key":"125_CR3","first-page":"2622","volume":"26","author":"A Saraux","year":"1999","unstructured":"Saraux A, Guedes C, Allain J, et al.: Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l\u2019Ouest. J Rheumatol 1999, 26:2622\u20132627.","journal-title":"J Rheumatol"},{"key":"125_CR4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden Van der","year":"1984","unstructured":"Van der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361\u2013368.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"125_CR5","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"J Sieper","year":"2009","unstructured":"\u2022\u2022 Sieper J, Rudwaleit M, Baraliakos X, et al.: The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009, 68(Suppl 2):ii1\u2013ii44. These new criteria for SpA will help us treat even early stages of the disease adequately.","journal-title":"Ann Rheum Dis"},{"key":"125_CR6","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","volume":"65","author":"J Zochling","year":"2006","unstructured":"Zochling J, van der Heijde D, Burgos-Vargas R, et al.: ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006, 65:442\u2013452.","journal-title":"Ann Rheum Dis"},{"key":"125_CR7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","volume":"62","author":"J Braun","year":"2003","unstructured":"Braun J, Pham T, Sieper J, et al.: International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003, 62:817\u2013824.","journal-title":"Ann Rheum Dis"},{"key":"125_CR8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","volume":"65","author":"J Braun","year":"2006","unstructured":"Braun J, Davis J, Dougados M, et al.: First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006, 65:316\u2013320.","journal-title":"Ann Rheum Dis"},{"key":"125_CR9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","volume":"38","author":"J Braun","year":"1995","unstructured":"Braun J, Bollow M, Neure L, et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995, 38:499\u2013505.","journal-title":"Arthritis Rheum"},{"key":"125_CR10","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","volume":"43","author":"J Brandt","year":"2000","unstructured":"Brandt J, Haibel H, Cornely D, et al.: Successful treatment of active ankylosing spondylitis with the anti-tumour necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000, 43:1346\u20131352.","journal-title":"Arthritis Rheum"},{"key":"125_CR11","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/1529-0131(200112)44:12<2936::AID-ART483>3.0.CO;2-M","volume":"44","author":"J Brandt","year":"2001","unstructured":"Brandt J, Haibel H, Reddig J, et al.: Treatment of patients with severe ankylosing spondylitis with infliximab\u2014a one year follow up. Arthritis Rheum 2001, 44:2936\u20132937.","journal-title":"Arthritis Rheum"},{"key":"125_CR12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, et al.: Treatment of active ankylosing spondylitis with infliximab\u2014a double-blind placebo controlled multicenter trial. Lancet 2002, 359:1187\u20131193.","journal-title":"Lancet"},{"key":"125_CR13","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D Heijde Van der","year":"2005","unstructured":"Van der Heijde D, Dijkmans B, Geusens P, et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582\u2013591.","journal-title":"Arthritis Rheum"},{"key":"125_CR14","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2004.029900","volume":"64","author":"SN Nikas","year":"2005","unstructured":"Nikas SN, Alamanos Y, Voulgari PV, et al.: Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis 2005, 64:940\u2013942.","journal-title":"Ann Rheum Dis"},{"key":"125_CR15","first-page":"558","volume":"33","author":"S Keeling","year":"2006","unstructured":"Keeling S, Oswald A, Russell AS, Maksymovych WP: Prospective observational analysis of the efficacy and safety of low-dose (3 mg\/kg) infliximab in ankylosing spondylitis: 4-year follow-up. J Rheumatol 2006, 33:558\u2013561.","journal-title":"J Rheumatol"},{"key":"125_CR16","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/kel156","volume":"45","author":"RN Jois","year":"2006","unstructured":"Jois RN, Leeder J, Gibb A, et al.: Low-dose infliximab treatment for ankylosing spondylitis\u2014clinically- and cost-effective. Rheumatology 2006, 45:1566\u20131569.","journal-title":"Rheumatology"},{"key":"125_CR17","first-page":"513","volume":"23","author":"P Sidiropoulos","year":"2005","unstructured":"Sidiropoulos P, Kritikos HD, Siakka P, et al.: Low dose of infliximab is inadequate in most patients with spondyloarthropathies. Clin Exp Rheumatol 2005, 23:513\u2013516.","journal-title":"Clin Exp Rheumatol"},{"key":"125_CR18","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3899\/jrheum.091042","volume":"37","author":"RD Inman","year":"2010","unstructured":"Inman RD, Maksymowych WP: A double-blind, placebo-controlled trial of low-dose infliximab in ankylosing spondylitis. J Rheumatol 2010, 37:1203\u20131210.","journal-title":"J Rheumatol"},{"key":"125_CR19","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.24001","volume":"59","author":"J Braun","year":"2008","unstructured":"Braun J, Deodhar A, Dijkmans B, et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008, 59:1270\u20131278.","journal-title":"Arthritis Rheum"},{"key":"125_CR20","unstructured":"Heldmann F, Brandt J, Listing J, et al.: European Ankylosing Spondylitis Infliximab Cohort (EASIC): long term efficacy of infliximab in patients with ankylosing spondylitis (AS) after 2 years of EASIC. Presented at the Annual Meeting of the European League Against Rheumatism. Copenhagen, Denmark; June 10\u201313, 2009."},{"key":"125_CR21","first-page":"510","volume":"34","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos X, Listing J, Rudwaleit M, et al.: Safety and efficacy of readministration of infliximab after long-term continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 2007, 34:510\u2013515.","journal-title":"J Rheumatol"},{"key":"125_CR22","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/ard.2007.075879","volume":"67","author":"J Braun","year":"2008","unstructured":"Braun J, Baraliakos X, Listing J, et al.: Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008, 67:340\u2013345.","journal-title":"Ann Rheum Dis"},{"key":"125_CR23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/art.23167","volume":"58","author":"M Breban","year":"2008","unstructured":"Breban M, Ravaud P, Claudepierre P, et al.: Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008, 58:88\u201397.","journal-title":"Arthritis Rheum"},{"key":"125_CR24","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/rheumatology\/ken207","volume":"47","author":"EK Li","year":"2008","unstructured":"Li EK, Griffith JF, Lee VW, et al.: Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology 2008, 47:1358\u20131363.","journal-title":"Rheumatology"},{"key":"125_CR25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/ard.2007.078139","volume":"67","author":"JC Davis Jr","year":"2008","unstructured":"Davis JC Jr, van der Heijde D, Braun J, et al.: Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008, 67:346\u2013352.","journal-title":"Ann Rheum Dis"},{"key":"125_CR26","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","volume":"48","author":"J Brandt","year":"2003","unstructured":"Brandt J, Khariouzov A, Listing J, et al.: Six months results of a German double-blind placebo controlled, phase III clinical trial of etanercept in active ankylosing spondylitis. Arthritis Rheum 2003, 48:1667\u20131675.","journal-title":"Arthritis Rheum"},{"key":"125_CR27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/rheumatology\/keh475","volume":"44","author":"J Brandt","year":"2005","unstructured":"Brandt J, Listing J, Haibel H, et al.: Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 2005, 44:342\u2013348.","journal-title":"Rheumatology"},{"key":"125_CR28","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","volume":"65","author":"D Heijde Van der","year":"2006","unstructured":"Van der Heijde D, Da Silva JC, Dougados M, et al.: Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006, 65:1572\u20131577.","journal-title":"Ann Rheum Dis"},{"key":"125_CR29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.2007.087270","volume":"68","author":"D Heijde Van der","year":"2009","unstructured":"Van der Heijde D, Schiff MH, Sieper J, et al.: Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009, 68:922\u2013929.","journal-title":"Ann Rheum Dis"},{"key":"125_CR30","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/rheumatology\/kep022","volume":"48","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Olivieri I, Boki KA, et al.: Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advance spinal fusion. Rheumatology 2009, 48:551\u2013557.","journal-title":"Rheumatology"},{"key":"125_CR31","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, van der Heijde D, et al.: Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo controlled, phase III trial. Arthritis Rheum 2008, 58:3402\u20133412.","journal-title":"Arthritis Rheum"},{"key":"125_CR32","doi-asserted-by":"crossref","first-page":"R104","DOI":"10.1186\/ar2496","volume":"10","author":"X Baraliakos","year":"2008","unstructured":"Baraliakos X, Listing J, Rudwaleit M, et al.: The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008, 10:R104.","journal-title":"Arthritis Res Ther"},{"key":"125_CR33","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D Heijde Van der","year":"2008","unstructured":"Van der Heijde D, Landew\u00e9 R, Einstein S, et al.: Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008, 58:1324\u20131331.","journal-title":"Arthritis Rheum"},{"key":"125_CR34","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D Heijde Van der","year":"2008","unstructured":"Van der Heijde D, Landew\u00e9 R, Baraliakos X, et al.; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group: Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008, 58:3063\u20133070.","journal-title":"Arthritis Rheum"},{"key":"125_CR35","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"D Heijde Van der","year":"2009","unstructured":"Van der Heijde D, Salonen D, Weissman BN, et al.: Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009, 11:R127.","journal-title":"Arthritis Res Ther"},{"key":"125_CR36","unstructured":"Baraliakos X, Heldmann F, van der Heijde D, et al.: Radiographic findings after 5 years of infliximab treatment in patients with ankylosing spondylitis. Presented at the Annual Meeting of the European League Against Rheumatism. Rome, Italy; June 16\u201319, 2010."},{"key":"125_CR37","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1136\/ard.2006.066415","volume":"66","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos X, Listing J, Rudwaleit M, et al.: Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007, 66:910\u2013915.","journal-title":"Ann Rheum Dis"},{"key":"125_CR38","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/art.24425","volume":"61","author":"X Baraliakos","year":"2009","unstructured":"\u2022 Baraliakos X, Listing J, Rudwaleit M, et al.: Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. Arthritis Rheum 2009, 61:764\u2013771. Involvement of the thoracic spine, which is often affected by inflammation in AS, in a scoring tool for radiographic progression provides a better sensitivity to change, taking into account that TNF blockers failed to show that they can prevent radiographic progression.","journal-title":"Arthritis Rheum"},{"key":"125_CR39","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3899\/jrheum.080871","volume":"36","author":"X Baraliakos","year":"2009","unstructured":"Baraliakos X, Listing J, von der Recke A, Braun J: The natural course of radiographic progression in ankylosing spondylitis\u2014evidence for major individual variations in a large proportion of patients. J Rheumatol 2009, 36:997\u20131002.","journal-title":"J Rheumatol"},{"key":"125_CR40","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1002\/art.24888","volume":"60","author":"H Appel","year":"2009","unstructured":"Appel H, Ruiz-Heiland G, Listing J, et al.: Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009, 60:3257\u20133262.","journal-title":"Arthritis Rheum"},{"key":"125_CR41","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/rheumatology\/kem166","volume":"46","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos X, Listing J, Brandt J, et al.: Radiographic progression in patients with ankylosing spondylitis after 4 years of treatment with the TNF-alpha antibody infliximab. Rheumatology 2007, 46:1450\u20131453.","journal-title":"Rheumatology"},{"key":"125_CR42","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","volume":"52","author":"J Braun","year":"2005","unstructured":"Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52:2447\u20132451.","journal-title":"Arthritis Rheum"},{"key":"125_CR43","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Rodevand E, Holck P, et al.: Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009, 68:696\u2013701.","journal-title":"Ann Rheum Dis"},{"key":"125_CR44","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22669","volume":"57","author":"J Braun","year":"2007","unstructured":"Braun J, Baraliakos X, Listing J, et al.: Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007, 57:639\u2013647.","journal-title":"Arthritis Rheum"},{"key":"125_CR45","doi-asserted-by":"crossref","unstructured":"Braun J, Rudwaleit M, Kary S, et al.: Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. Rheumatology 2010 May 6 (Epub ahead of print).","DOI":"10.1093\/rheumatology\/keq129"},{"key":"125_CR46","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2007.073098","volume":"67","author":"M Rudwaleit","year":"2008","unstructured":"Rudwaleit M, Schwarzlose S, Hilgert ES, et al.: MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008, 67:1276\u20131281.","journal-title":"Ann Rheum Dis"},{"key":"125_CR47","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","volume":"36","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Claudepierre P, Wordsworth P, et al.: Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009, 36:801\u2013808.","journal-title":"J Rheumatol"},{"key":"125_CR48","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.24838","volume":"61","author":"MK Vries De","year":"2009","unstructured":"De Vries MK, van Eick IC, van der Horst-Bruinsma IE, et al.: Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009, 61:1484\u20131490.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 43","key":"125_CR49","first-page":"S88","volume":"24","author":"J Zochling","year":"2006","unstructured":"Zochling J, Braun J: Remission in ankylosing spondylitis. Clin Exp Rheumatol 2006, 24(Suppl 43):S88\u2013S92.","journal-title":"Clin Exp Rheumatol"},{"key":"125_CR50","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1136\/ard.2008.092494","volume":"68","author":"M Neidhart","year":"2009","unstructured":"Neidhart M, Baraliakos X, Seemayer C, et al.: Expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in long-standing ankylosing spondylitis. Ann Rheum Dis 2009, 68:1334\u20131339.","journal-title":"Ann Rheum Dis"},{"key":"125_CR51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/ard.2006.057745","volume":"66","author":"MK Vries De","year":"2007","unstructured":"De Vries MK, Wolbink GJ, Stapel SO, et al.: Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis 2007, 66:133\u2013134.","journal-title":"Ann Rheum Dis"},{"key":"125_CR52","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1136\/ard.2009.109702","volume":"68","author":"MK Vries De","year":"2009","unstructured":"De Vries MK, Brouwer E, van der Horst-Bruinsma IE, et al.: Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 2009, 68:1787\u20131788.","journal-title":"Ann Rheum Dis"},{"key":"125_CR53","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/ard.2007.073569","volume":"66","author":"F Conti","year":"2007","unstructured":"Conti F, Ceccarelli F, Marocchi E, et al.: Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007, 66:1393\u20131397.","journal-title":"Ann Rheum Dis"},{"key":"125_CR54","first-page":"1109","volume":"7","author":"W Mau","year":"1988","unstructured":"Mau W, Zeidler H, Mau R, et al.: Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year follow-up. J Rheumatol 1988, 7:1109\u20131114.","journal-title":"J Rheumatol"},{"key":"125_CR55","first-page":"118","volume":"29","author":"J Brandt","year":"2002","unstructured":"Brandt J, Haibel H, Reddig J, et al.: Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-\u03b1 monoclonal antibody infliximab. J Rheumatol 2002, 29:118\u2013122.","journal-title":"J Rheumatol"},{"key":"125_CR56","first-page":"531","volume":"31","author":"J Brandt","year":"2004","unstructured":"Brandt J, Khariouzov A, Listing J, et al.: Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004, 31:531\u2013538.","journal-title":"J Rheumatol"},{"key":"125_CR57","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","volume":"58","author":"H Haibel","year":"2008","unstructured":"Haibel H, Rudwaleit M, Listing J, et al.: Efficacy of adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008, 58:1981\u20131991.","journal-title":"Arthritis Rheum"},{"key":"125_CR58","unstructured":"Amtenbrink AL, Haibel H, Rudwaleit M, et al.: Adalimumab successfully re-treats and maintains long-term efficacy in axial spondyloarthritis (SpA) patients without radiographic sacroiliitis who relapse following adalimumab withdrawal [abstract 1108]. Presented at the Annual Meeting of the American College of Rheumatology. San Francisco, CA; October 24\u201329, 2008."},{"key":"125_CR59","unstructured":"Haibel H, Rios V, Hermann KG, et al.: No progression of chronic sacroiliac changes in patients with active, non-radiographic axial spondyloarthritis treated with adalimumab over 52 weeks [abstract 1798]. Presented at the Annual Meeting of the American College of Rheumatology. Philadelphia, PA; October 16\u201321, 2009."},{"key":"125_CR60","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","volume":"60","author":"N Barkham","year":"2009","unstructured":"Barkham N, Keen HI, Coates LC, et al.: Clinical and imaging efficacy of infliximab in HLA B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009, 60:946\u2013954.","journal-title":"Arthritis Rheum"},{"key":"125_CR61","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.22600","volume":"56","author":"S Schneeweiss","year":"2007","unstructured":"Schneeweiss S, Setoguchi S, Weinblatt ME, et al.: Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:1754\u20131764.","journal-title":"Arthritis Rheum"},{"key":"125_CR62","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/ard.2008.091926","volume":"68","author":"A Zink","year":"2009","unstructured":"Zink A, Askling J, Dixon WG, et al.: European biologicals registers: methodology, selected results, and perspectives. Ann Rheum Dis 2009, 68:1240\u20131246.","journal-title":"Ann Rheum Dis"},{"key":"125_CR63","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.autrev.2009.07.006","volume":"9","author":"FB Pallavicini","year":"2010","unstructured":"Pallavicini FB, Caporali R, Sarzi-Puttini P, et al.: Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 2010, 9:175\u2013180.","journal-title":"Autoimmun Rev"},{"key":"125_CR64","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","volume":"68","author":"J Askling","year":"2009","unstructured":"Askling J, Baecklund E, Granath F, et al.: Anti-tumor necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics register. Ann Rheum Dis 2009, 68:648\u2013653.","journal-title":"Ann Rheum Dis"},{"key":"125_CR65","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","volume":"69","author":"X Mariette","year":"2010","unstructured":"Mariette X, Tubach F, Bagheri H, et al.: Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010, 69:400\u2013408.","journal-title":"Ann Rheum Dis"},{"key":"125_CR66","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/ard.2005.047514","volume":"65","author":"J Askling","year":"2006","unstructured":"Askling J, Klareskog L, Blomqvist P, et al.: Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006, 65:1184\u20131187.","journal-title":"Ann Rheum Dis"},{"key":"125_CR67","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/ard.2004.020800","volume":"63","author":"AL Tan","year":"2004","unstructured":"Tan AL, Marzo-Ortega H, O\u2019Connor P, et al.: Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004, 63:1041\u20131045.","journal-title":"Ann Rheum Dis"},{"key":"125_CR68","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2004.023176","volume":"64","author":"H Haibel","year":"2005","unstructured":"Haibel H, Rudwaleit M, Listing J, et al.: Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005, 64:296\u2013298.","journal-title":"Ann Rheum Dis"},{"key":"125_CR69","unstructured":"Song I, Heldmann F, Rudwaleit M, et al.: Major clinical response of rituximab in active TNF-blocker-naive patients with ankylosing spondylitis but not in TNF-blocker-failure patients-an open label clinical trial. Presented at the Annual Meeting of the European League Against Rheumatism. Copenhagen, Denmark; June 10\u201313, 2009."},{"key":"125_CR70","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10067-006-0283-5","volume":"26","author":"A Bal","year":"2007","unstructured":"Bal A, Unlu E, Bahar G, et al.: Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007, 26:211\u2013215.","journal-title":"Clin Rheumatol"},{"key":"125_CR71","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/ard.2007.071605","volume":"67","author":"S Visvanathan","year":"2008","unstructured":"Visvanathan S, Wagner C, Marini JC, et al.: Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008, 67:511\u2013517.","journal-title":"Ann Rheum Dis"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0125-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-010-0125-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0125-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T11:40:42Z","timestamp":1740310842000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-010-0125-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,28]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["125"],"URL":"https:\/\/doi.org\/10.1007\/s11926-010-0125-y","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"type":"print","value":"1523-3774"},{"type":"electronic","value":"1534-6307"}],"subject":[],"published":{"date-parts":[[2010,7,28]]}}}